BSE Live
Mar 16, 16:01Prev. Close
1560.80
Open Price
1579.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 16, 16:03Prev. Close
1561.30
Open Price
1565.60
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Ipca Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 25.04 | 24.99 | 25.09 | 25.00 | 25.00 | |
| Total Share Capital | 25.04 | 24.99 | 25.09 | 25.00 | 25.00 | |
| Reserves and Surplus | 849.82 | 613.52 | 582.57 | 461.02 | 360.89 | |
| Total Reserves and Surplus | 849.82 | 613.52 | 582.57 | 461.02 | 360.89 | |
| Total Shareholders Funds | 874.86 | 638.51 | 607.66 | 486.02 | 385.89 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 219.85 | 231.46 | 181.83 | 122.09 | 1.94 | |
| Deferred Tax Liabilities [Net] | 82.86 | 68.16 | 59.01 | 53.07 | 48.95 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 302.71 | 299.62 | 240.84 | 175.16 | 50.89 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 233.62 | 218.76 | 170.67 | 116.45 | 194.60 | |
| Trade Payables | 119.59 | 92.81 | 94.41 | 88.57 | 76.01 | |
| Other Current Liabilities | 64.84 | 101.29 | 43.24 | 34.84 | 31.05 | |
| Short Term Provisions | 153.74 | 111.06 | 121.66 | 86.69 | 13.02 | |
| Total Current Liabilities | 571.79 | 523.92 | 429.98 | 326.55 | 314.68 | |
| Total Capital And Liabilities | 1,749.37 | 1,462.08 | 1,278.52 | 987.77 | 751.47 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 630.56 | 557.70 | 410.19 | 371.37 | 340.77 | |
| Intangible Assets | 5.91 | 5.33 | 3.24 | 3.11 | 3.03 | |
| Capital Work-In-Progress | 38.28 | 16.69 | 127.61 | 57.00 | 29.72 | |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 674.75 | 579.72 | 541.04 | 431.48 | 373.52 | |
| Non-Current Investments | 49.42 | 57.03 | 31.91 | 24.92 | 13.93 | |
| Deferred Tax Assets [Net] | 3.55 | 3.05 | 1.65 | 1.88 | 1.06 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Assets | 727.72 | 639.80 | 574.60 | 458.28 | 388.51 | |
| CURRENT ASSETS | ||||||
| Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Inventories | 370.84 | 299.83 | 259.52 | 232.21 | 183.32 | |
| Trade Receivables | 391.91 | 342.77 | 271.81 | 180.98 | 142.94 | |
| Cash And Cash Equivalents | 8.29 | 6.42 | 7.59 | 5.57 | 3.67 | |
| Short Term Loans And Advances | 214.22 | 173.26 | 165.00 | 110.73 | 33.02 | |
| OtherCurrentAssets | 36.39 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 1,021.65 | 822.28 | 703.92 | 529.49 | 362.96 | |
| Total Assets | 1,749.37 | 1,462.08 | 1,278.52 | 987.77 | 751.47 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 130.59 | 109.41 | 28.96 | 27.48 | 38.38 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 205.20 | 155.81 | 126.18 | 120.34 | 102.38 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 40.96 | 20.94 | 15.38 | 10.23 | 12.65 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 83.27 | 67.56 | 56.75 | 53.24 | 42.87 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 783.32 | 657.40 | 516.41 | 467.31 | 385.77 | |
| Other Earnings | 2.40 | 3.56 | 3.43 | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 20.90 | 20.90 | 20.90 | 20.90 | 20.90 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 10.88 | 4.49 | 6.53 | 2.68 | -- | |
| Non-Current Investments Unquoted Book Value | 39.84 | 44.51 | 22.39 | 19.83 | 13.93 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | -- | -- | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
06.03.2026
Buy Ipca Laboratories; target of Rs 1800: Prabhudas Lilladher
18.02.2026
Buy Ipca Laboratories; target of Rs 1710: Prabhudas Lilladher
17.02.2026
09.02.2026
26.11.2025
Ipca Labs Consolidated September 2025 Net Sales at Rs 2,556.50 crore, up 8.56% Y-o-Y
24.11.2025
Ipca Labs Standalone September 2025 Net Sales at Rs 1,930.32 crore, up 6.59% Y-o-Y
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
13.07.2022
Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct
08.07.2022
Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher
14.04.2022
Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher
13.01.2022
Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher
16.03.2026
15.03.2026
13.03.2026
13.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth